Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Phase 3 combination study comparing tanespimycin (KOS-953) plus bortezomib to bortezomib alone in patients with multiple myeloma in first relapse after failure of previous anti-cancer therapy and/or bone marrow transplantation. Primary objective is to compare the progression-free survival (PFS) associated with the use of tanespimycin (KOS-953) in combination with bortezomib versus that associated with administration of bortezomib alone.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Good Performance Status
Documented evidence of multiple myeloma
Documented progression of disease after initial response to one line of therapy
Measurable disease (serum M-protein \>.5g/dl or \> 200 mg urinary M protein excretion)
You may not be if
Prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor
Known active infections of HAV, HBV, HCV, or HIV
Administration of chemotherapy, radiation therapy, or immune therapy within 21 days prior to randomization.
Acute diffuse infiltrate pulmonary disease or pericardial dise
